Clinical trials: Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
- Trial name
- NCT04134169
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to…
- Trial name
- SELECT-BEYOND (NCT02706847)
- Testing
- Upadacitinib
- Where
- 188 sites in United States, Australia and 25 more
- Volunteers
- 499 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to assess the efficacy and safety of tocilizumab vs placebo, in combination with stable, ongoing therapy, with regard to reduction in signs and symptoms in patients with moderate to severe active RA…
- Trial name
- NCT01211834
- Testing
- tocilizumab, DMARDs
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- JW Pharmaceutical
Rheumatoid Arthritis
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01663506
- Where
- 3 sites in Estonia
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with traditional Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy in…
- Trial name
- NCT00106574
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 146 sites in United States, Argentina and 17 more
- Volunteers
- 1,220 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for…
- Trial name
- NCT06972446
- Testing
- Lutikizumab, Ravagalimab
- Where
- 96 sites in United States, Canada and 10 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Chronic Pain
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results…
- Trial name
- NCT01223365
- Testing
- Hydrocodone ER
- Where
- 54 sites in United States
- Volunteers
- 330 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Active, Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
It is not fully clear how rheumatoid arthritis originates and develops, but it is understood that multiple genetic and environmental factors interact to trigger its onset.
- Trial name
- NCT00642629
- Testing
- STA 5326 mesylate
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Synta Pharmaceuticals Corp.
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
This study [contRAst 1 (201790: NCT03980483)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult…
- Trial name
- contRAst 1 (NCT03980483)
- Testing
- GSK3196165 (Otilimab), Tofacitinib 5 mg
- Where
- 76 sites in China, Hungary and 8 more
- Volunteers
- 1,537 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX).
- Trial name
- NCT00083759
- Testing
- natalizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- Biogen
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT01283971
- Testing
- tocilizumab [RoActemra/Actemra], adalimumab, methotrexate
- Where
- 170 sites in United States, Denmark and 10 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Primary objective of the study is to establish a 3-way PK similarity bridge between MabionCD20 (candidate biosimilar to rituximab), MabThera® (EU-sourced rituximab) and Rituxan® (US-sourced rituximab) following the administration…
- Trial name
- MABRIDGE (NCT04680962)
- Testing
- MabionCD20 (candidate biosimilar to rituximab), MabThera®, Rituxan®
- Sponsor
- Mabion SA
Rheumatoid Arthritis
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX.
- Trial name
- MUSICA (NCT01185288)
- Testing
- Adalimumab, Methotrexate
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 309 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs
This open-label, single arm study will evaluate the effect of RoActemra/Actemra in combination with methotrexate on articular damage in the hand (synovitis/osteitis and erosions) in patients with moderate to severe rheumatoid…
- Trial name
- NCT01878318
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early moderate to severe rheumatoid arthritis who completed the WA19926…
- Trial name
- NCT01730456
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- North Macedonia
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the…
- Trial name
- NCT01664598
- Testing
- Tocilizumab
- Where
- 12 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Rhematoid Arthritis
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with…
- Trial name
- ORAL STRATEGY (NCT02187055)
- Testing
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Where
- 215 sites in United States, Argentina and 23 more
- Volunteers
- 1,152 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
This observational study will evaluate the presence and evolution of fatigue on treatment with RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis who have an inadequate response to at least…
- Trial name
- NCT01667458
- Where
- 18 sites in Belgium, Luxembourg
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
This is a randomized, double-blind, multi-center, parallel-group study to evaluate the efficacy and safety of subcutaneous (SC) tocilizumab (162 milligrams [mg] every 2 weeks [Q2W]) given as monotherapy and in combination with…
- Trial name
- NCT03155347
- Testing
- Tocilizumab, MTX
- Where
- 20 sites in China
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to…
- Trial name
- NCT02608112
- Testing
- Methotrexate, Tocilizumab
- Where
- 77 sites in France
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche